Biomarkers in Lung Cancer

Catherine R Sears; Peter J Mazzone

doi:10.1016/j.ccm.2019.10.004

Biomarkers in Lung Cancer

Clin Chest Med. 2020 Mar;41(1):115-127. doi: 10.1016/j.ccm.2019.10.004. Epub 2020 Jan 2.

Authors

Catherine R Sears¹, Peter J Mazzone²

Affiliations

¹ Department of Medicine, Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, 980 West Walnut Street, Room R3-C400, Indianapolis, IN, USA. Electronic address: [email protected].
² Lung Cancer Program, Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, A90, Cleveland, OH 44195, USA.

PMID: 32008624
DOI: 10.1016/j.ccm.2019.10.004

Abstract

Biomarkers that focus on lung cancer risk assessment, detection, prognosis, diagnosis, and personalized treatment are in various stages of development. This article provides an overview of lung cancer biomarker development, focusing on clinical utility and highlighting 2 unmet clinical needs: selection of high-risk patients for lung cancer screening and differentiation of early lung cancer from benign pulmonary nodules. The authors highlight biomarkers under development and those lung cancer screening and nodule management biomarkers post-clinical validation. Finally, trends in lung cancer biomarker development that may improve accuracy and accelerate implementation in practice are discussed.

Keywords: Clinical utility; Lung cancer screening; Lung nodules; Next-generation sequencing; Radiomics; Trial design.

Publication types

Review

MeSH terms

Biomarkers / metabolism*
Early Detection of Cancer / methods*
Female
Humans
Lung Neoplasms / diagnosis*
Male
Prognosis

Substances

Biomarkers